Cargando…

Optimized Alectinib Dose Regimen for Treatment of Patients With ALK‐Positive Non‐Small Cell Lung Cancer Based on Robust Pharmacometric Analyses and Clinical Evidence

Detalles Bibliográficos
Autores principales:	Frey, Nicolas, Bordogna, Walter, Balas, Bogdana, Ruf, Thorsten, Archer, Venice, Guerini, Elena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Perspectives
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291499/ https://www.ncbi.nlm.nih.gov/pubmed/34365647 http://dx.doi.org/10.1002/cpt.2373

Ejemplares similares

Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first‐line treatment of anaplastic lymphoma kinase–positive non‐small cell lung cancer
por: Hsu, Joy C., et al.
Publicado: (2021)

Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer
por: Morcos, Peter N., et al.
Publicado: (2018)

Phase 2 prospective analysis of alectinib in ALK-positive, crizotinib-resistant non-small-cell lung cancer
por: Shaw, Alice T., et al.
Publicado: (2015)

Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib
por: Morcos, Peter N., et al.
Publicado: (2018)

Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatment-Naive Advanced ALK-Positive NSCLC
por: Noé, Johannes, et al.
Publicado: (2022)

Pharmacometrics: Focus on the Patient
por: Dumitrescu, T Pene, et al.
Publicado: (2015)

Response to “Pharmacometric Approach to Evaluate Drug Dosing Adherence”
por: Ding, Junjie, et al.
Publicado: (2020)

Opinion: The Pharmacometrics of Infectious Disease
por: Davies, G R, et al.
Publicado: (2013)

Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib
por: Dziadziuszko, R., et al.
Publicado: (2022)

Time to Expect More From Pharmacometrics
por: Barrett, Jeffrey S.
Publicado: (2020)

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer
por: Yang, James Chih-Hsin, et al.
Publicado: (2017)

Role of pharmacometrics and systems pharmacology in facilitating efficient dose optimization in oncology
por: Jayachandran, Priya, et al.
Publicado: (2023)

Perspective on the State of Pharmacometrics and Systems Pharmacology Integration
por: Trame, Mirjam N., et al.
Publicado: (2018)

Artificial Intelligence and Pharmacometrics: Time to Embrace, Capitalize, and Advance?
por: Chaturvedula, Ayyappa, et al.
Publicado: (2019)

Meeting Report: PMDA Public Workshop on Pharmacometrics at Japan
por: Kijima, Shinichi, et al.
Publicado: (2020)

R and nlmixr as a gateway between statistics and pharmacometrics
por: Fidler, Matthew, et al.
Publicado: (2021)

Where Do PBPK Models Stand in Pharmacometrics and Systems Pharmacology?
por: Jamei, Masoud
Publicado: (2020)

Variable or variate? A conundrum in pharmacometrics exposure–response models
por: Grisic, Ana‐Marija, et al.
Publicado: (2022)

Barriers to global pharmacometrics: educational challenges and opportunities across the globe
por: Michelet, Robin, et al.
Publicado: (2023)

Sensitivity of eight types of ALK fusion variant to alectinib in ALK-transformed cells
por: Furugaki, Koh, et al.
Publicado: (2021)

Progressive renal insufficiency related to ALK inhibitor, alectinib
por: Nagai, Kojiro, et al.
Publicado: (2018)

Pharmacometrics: Opportunity for Reducing Disease Burden in the Developing World: The Case of Africa
por: Pillai, G, et al.
Publicado: (2013)

The Mathematical and Computational Sciences Special Interest Group of the International Society of Pharmacometrics
por: Moore, Helen
Publicado: (2019)

Pharmacometrics in Australasia—Twenty Years of Population Approach Group of Australia and New Zealand
por: Hennig, Stefanie, et al.
Publicado: (2019)

The Asian Pharmacometrics Network: The historical background, establishment, objectives and roles, and recent activities
por: Kaibara, Atsunori, et al.
Publicado: (2022)

2549. Pharmacometric Analyses to Support Sulbactam-Durlobactam (SUL-DUR) Dosing Regimens in Patients with Altered Renal Function
por: Larson, Kajal, et al.
Publicado: (2023)

ALK-Positive Squamous Cell Carcinoma Dramatically Responded to Alectinib
por: Sagawa, Ray, et al.
Publicado: (2018)

Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
por: Imanishi, Naoko, et al.
Publicado: (2018)

STRN-ALK, A Novel In-Frame Fusion With Response to Alectinib
por: Nagasaka, Misako, et al.
Publicado: (2020)

Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC
por: Ulhoi, Maiken Parm, et al.
Publicado: (2021)

Alectinib for Miliary Lung Metastasis in ALK-Positive Lung Adenocarcinoma
por: Satoh, Hironori, et al.
Publicado: (2021)

Novel ALK Fusion, PPFIBP1-ALK, in Pancreatic Ductal Adenocarcinoma Responsive to Alectinib and Lorlatinib
por: Gower, Arjan, et al.
Publicado: (2020)

Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2018)

Pharmacometrics Markup Language (PharmML): Opening New Perspectives for Model Exchange in Drug Development
por: Swat, MJ, et al.
Publicado: (2015)

Approaching Pharmacometrics as a Paleontologist Would: Recovering the Links Between Drugs and the Body Through Reconstruction
por: Craig, M, et al.
Publicado: (2016)

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
por: Alam, Muhammad Wasi, et al.
Publicado: (2019)

The ALK inhibitors, alectinib and ceritinib, induce ALK‐independent and STAT3‐dependent glioblastoma cell death
por: Kawauchi, Daisuke, et al.
Publicado: (2021)

STRN-ALK Fusion–Positive Case of Breast Cancer With Response to Alectinib
por: Kelly, Andrew D., et al.
Publicado: (2021)

Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma
por: Adashek, Jacob J., et al.
Publicado: (2023)

Pharmacometrics, Physiologically Based Pharmacokinetics, Quantitative Systems Pharmacology—What's Next?—Joining Mechanistic and Epidemiological Approaches
por: Schmidt, Stephan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7fdds3istv08tvprvojdcsgga2